Editorial for “Preoperative MRI‐Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR‐TKI Treatment in NSCLC”

This publication has 8 references indexed in Scilit:

• Preoperative MRI‐Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR‐TKI Treatment in NSCLC
  Journal of Magnetic Resonance Imaging, 2022
• Predicting cancer outcomes with radiomics and artificial intelligence in radiology
  Nature Reviews Clinical Oncology, 2021
• Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer
  Cancer Management and Research, 2021
• Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
  Biochemistry, 2020
• Cancer treatment and survivorship statistics, 2019
  CA: A Cancer Journal for Clinicians, 2019
• Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
  Neuro-Oncology, 2014
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
  Clinical Cancer Research, 2013
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004